Bicycle Therapeutics (BCYC) Receivables - Other (2019 - 2026)

Bicycle Therapeutics (BCYC) has 8 years of Receivables - Other data on file, last reported at $40.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 11.44% year-over-year to $40.9 million; the trailing twelve-month figure through Mar 2026 stood at $40.9 million (down 11.44% YoY), and the FY2025 full-year result was $35.6 million, changed 0.15% from the prior year.
• Receivables - Other for Q1 2026 stood at $40.9 million, up from $35.6 million in the prior quarter.
• Across five years, Receivables - Other topped out at $67.3 million in Q3 2025 and bottomed at $11.4 million in Q3 2022.
• The 5-year median for Receivables - Other is $35.6 million (2025), against an average of $33.6 million.
• The widest annual swing landed in 2023, when Receivables - Other fell 20.81%; it then jumped 260.47% in 2024.
• A 5-year view of Receivables - Other shows it stood at $19.2 million in 2022, then grew by 25.45% to $24.0 million in 2023, then soared by 48.31% to $35.7 million in 2024, then retreated by 0.15% to $35.6 million in 2025, then gained by 14.94% to $40.9 million in 2026.
• The last three Receivables - Other figures came in at $40.9 million (Q1 2026), $35.6 million (Q4 2025), and $67.3 million (Q3 2025), per Business Quant data.

Peer Comparison